Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$111.70 -0.5%	$106.55	$72.21 ▼ $139.13	$5.53B	0.46	666,483 shs	453,651 shs
BHVN Biohaven	$14.04 -7.1%	$15.31	$13.04 ▼ $55.70	$1.54B	0.91	1.32 million shs	1.88 million shs
LNTH Lantheus	$70.18 -4.6%	$78.80	$69.12 ▼ $118.71	$5.09B	0.12	980,999 shs	1.35 million shs
NUVL Nuvalent	$83.40 -2.7%	$77.21	$55.54 ▼ $113.51	$6.15B	1.31	506,626 shs	334,196 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+0.83%	+1.36%	+10.47%	+7.45%	+34.03%
BHVN Biohaven	+13.66%	+0.85%	+4.13%	-25.62%	-58.18%
LNTH Lantheus	-1.09%	-12.20%	-5.54%	-27.36%	-39.48%
NUVL Nuvalent	+0.28%	+4.41%	+12.66%	+19.61%	+6.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.7309 of 5 stars	4.5	1.0	4.5	2.6	4.2	0.6
BHVN Biohaven	3.3597 of 5 stars	4.5	1.0	0.0	2.8	2.5	0.6
LNTH Lantheus	4.6279 of 5 stars	3.4	2.0	4.2	3.4	2.5	1.9
NUVL Nuvalent	3.1882 of 5 stars	4.6	1.0	0.0	2.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	54.28% Upside
BHVN Biohaven	3.07	Buy	$58.46	316.39% Upside
LNTH Lantheus	2.83	Moderate Buy	$131.20	86.95% Upside
NUVL Nuvalent	3.17	Buy	$119.60	43.41% Upside

Current Analyst Ratings Breakdown

Latest BHVN, NUVL, LNTH, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
6/30/2025	NUVL Nuvalent	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	NUVL Nuvalent	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$105.00 ➝ $112.00
6/24/2025	NUVL Nuvalent	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$115.00
6/24/2025	NUVL Nuvalent	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$125.00 ➝ $140.00
6/24/2025	NUVL Nuvalent	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$110.00 ➝ $130.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/18/2025	BHVN Biohaven	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$68.00 ➝ $55.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	14.26	N/A	N/A	$1.18 per share	94.66
BHVN Biohaven	N/A	N/A	N/A	N/A	$4.19 per share	N/A
LNTH Lantheus	$1.53B	3.17	$6.76 per share	10.38	$15.65 per share	4.48
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	39.61	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
BHVN Biohaven	-$846.42M	-$9.36	N/A	N/A	N/A	N/A	-257.07%	-164.01%	8/5/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	19.94	11.12	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.39	N/A	N/A	N/A	N/A	-31.35%	-29.27%	8/14/2025 (Estimated)

Latest BHVN, NUVL, LNTH, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2025	BHVN Biohaven	-$1.94	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	NUVL Nuvalent	-$1.27	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
7/30/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
BHVN Biohaven	N/A	2.33	2.33
LNTH Lantheus	0.49	5.74	5.46
NUVL Nuvalent	N/A	14.48	14.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
BHVN Biohaven	88.78%
LNTH Lantheus	99.06%
NUVL Nuvalent	97.26%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
BHVN Biohaven	16.00%
LNTH Lantheus	1.50%
NUVL Nuvalent	10.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
BHVN Biohaven	239	102.11 million	85.78 million	Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable

BHVN, NUVL, LNTH, and AXSM Headlines

Recent News About These Companies

Nuvalent, Inc. (NASDAQ:NUVL) CFO Alexandra Balcom Sells 5,300 Shares

1 hour ago | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) CFO Sells $1,250,970.00 in Stock

1 hour ago | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) CEO Sells $2,221,290.00 in Stock

1 hour ago | marketbeat.com

Alexandra Balcom Sells 5,300 Shares of Nuvalent, Inc. (NASDAQ:NUVL) Stock

July 18 at 9:36 AM | insidertrades.com

Edgestream Partners L.P. Boosts Position in Nuvalent, Inc. (NASDAQ:NUVL)

July 16 at 5:16 AM | marketbeat.com

Brokerages Set Nuvalent, Inc. (NASDAQ:NUVL) Price Target at $119.60

July 13, 2025 | americanbankingnews.com

Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells $174,088.20 in Stock

July 11, 2025 | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells $439,890.00 in Stock

July 11, 2025 | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of "Buy" from Analysts

July 10, 2025 | marketbeat.com

Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer

July 6, 2025 | msn.com

Viola Zhu - NUVL | Nuvalent Inc. Cl A - Wall Street Journal

July 3, 2025 | wsj.com

Nuvalent (NASDAQ:NUVL) Stock Rating Upgraded by The Goldman Sachs Group

July 2, 2025 | marketbeat.com

Alexandra Balcom Sells 20,000 Shares of Nuvalent, Inc. (NASDAQ:NUVL) Stock

July 2, 2025 | insidertrades.com

Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) CFO Sells 20,000 Shares of Stock

July 1, 2025 | marketbeat.com

Henry E. Pelish Sells 2,170 Shares of Nuvalent, Inc. (NASDAQ:NUVL) Stock

June 28, 2025 | insidertrades.com

Nuvalent, Inc. (NUVL) Latest Stock News & Headlines - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells 2,170 Shares of Stock

June 27, 2025 | marketbeat.com

Henry E. Pelish Sells 8,630 Shares of Nuvalent, Inc. (NASDAQ:NUVL) Stock

June 27, 2025 | marketbeat.com

Nuvalent FY2026 EPS Estimate Reduced by Leerink Partnrs

June 27, 2025 | marketbeat.com

HC Wainwright Issues Positive Estimate for Nuvalent Earnings

June 26, 2025 | marketbeat.com

Nuvalent price target raised to $140 from $125 at Leerink

June 26, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN, NUVL, LNTH, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$111.70 -0.54 (-0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$111.42 -0.28 (-0.25%)

As of 06:52 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Biohaven NYSE:BHVN

$14.04 -1.07 (-7.08%)

Closing price 03:59 PM Eastern

Extended Trading

$14.10 +0.06 (+0.43%)

As of 07:59 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Lantheus NASDAQ:LNTH

$70.18 -3.42 (-4.65%)

Closing price 04:00 PM Eastern

Extended Trading

$70.92 +0.73 (+1.05%)

As of 07:59 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Nuvalent NASDAQ:NUVL

$83.40 -2.29 (-2.67%)

Closing price 04:00 PM Eastern

Extended Trading

$83.38 -0.02 (-0.02%)

As of 04:20 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time